The Asia Pacific kidney cancer therapeutics and diagnostics market is projected to record a CAGR of 5.92% during the forecast period, 2019-2028. The surging number of kidney cancer cases in the region is primarily driving the growth of the market. South Korea, Japan, India, Vietnam, Thailand, Australia & New Zealand, Indonesia, Vietnam, and the rest of Asia Pacific, are analyzed for evaluating the Asia Pacific kidney cancer therapeutics and diagnostics market growth. In China, the aging population, unhealthy dietary habits, and obesity, are causing an increase in the number of kidney cancer cases.
ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2019-2028
Asia Pacific Kidney Cancer Therapeutics and Diagnostics Market by Cancer Type (Clear Cell Rcc, Papillary Rcc, Chromophobe Rcc, Urothelial Carcinoma/transitional Cell Carcinoma, Other Kidney Cancers) by Component (Drugs (Drugs by Therapeutic Class (Targeted Therapy, Immunotherapy, Other Therapeutic Class), Drugs by Pharmacologic Class(Angiogenesis Inhibitors, Mtor Inhibitors, Monoclonal Antibodies, Cytokine Immunotherapy (Il-2))), Diagnostics) and by Geography.
The Asia Pacific kidney cancer therapeutics and diagnostics market is projected to record a CAGR of 5.92% during the forecast period, 2019-2028. The surging number of kidney cancer cases in the region is primarily driving the growth of the market.
To know more about this report, request a free sample copy
South Korea, Japan, India, Vietnam, Thailand, Australia & New Zealand, Indonesia, Vietnam, and the rest of Asia Pacific, are analyzed for evaluating the Asia Pacific kidney cancer therapeutics and diagnostics market growth. In China, the aging population, unhealthy dietary habits, and obesity, are causing an increase in the number of kidney cancer cases. Cigarette smoking is prevalent, and adds to the burden in the country. In 2018, 70,047 new cases were reported, along with 43,486 deaths, as per Globocan. The risk factors for kidney cancer are evaluated to be high in China. The rising awareness with regard to diagnosis and treatment of kidney cancer and growing R&D initiatives are estimated to boost the market growth in the country.
In South Korea, the advancing healthcare infrastructure and new product launches are projected to influence market growth. The Ministry of Food and Drug Safety approved Cabometyx in September 2017, as a second-line treatment for renal cell carcinoma (RCC). The collaborations between major market players and research organizations are aimed at developing innovative cancer treatments. Regeneron Pharmaceuticals Inc and SillaJen Inc announced a new supply agreement in May 2017 for a Phase 1b dose-escalation study in renal cell carcinoma.
Pfizer Inc discovers, manufactures, and markets products like consumer healthcare products, medicines, and vaccines. The company supplies products for treating cardiovascular, respiratory, neurological problems, ophthalmic diseases, etc. The product portfolio includes SUTENT and INLYTA. The company has its operations in the Asia Pacific, the Americas, the Middle East & Africa, etc.
To request a free sample copy of this report, please complete the form below:
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
- EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
- MARKET DYNAMICS
- MARKET DEFINITION
- KEY DRIVERS
- GROWING PREVALENCE OF KIDNEY CANCER CASES
- INCREASING USAGES OF MINIMALLY INVASIVE PROCESSES
- SURGING RESEARCH AND DEVELOPMENT EXPENDITURE
- KEY RESTRAINTS
- HIGH COSTS ASSOCIATED WITH THE TREATMENT AND DIAGNOSIS OF KIDNEY CANCER
- LOW RATE OF SUCCESS IN THE CLINICAL TRIALS OF KIDNEY CANCER DRUGS
- STRINGENT REGULATIONS
- KEY ANALYTICS
- PORTER’S FIVE FORCE ANALYSIS
- THREAT OF NEW ENTRY
- THREAT OF SUBSTITUTION
- BUYER’S POWER
- SUPPLIER’S POWER
- COMPETITIVE RIVALRY
- IMPACT OF COVID-19 ON KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- KEY INVESTMENT INSIGHT
- PORTER’S FIVE FORCE ANALYSIS
- MARKET BY CANCER TYPE
- CLEAR CELL RCC
- PAPILLARY RCC
- CHROMOPHOBE RCC
- UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA
- OTHER KIDNEY CANCERS
- MARKET BY COMPONENT
- DRUGS
- DRUGS BY THERAPEUTIC CLASS
- TARGETED THERAPY
- IMMUNOTHERAPY
- OTHER THERAPEUTIC CLASS
- DRUGS BY PHARMACOLOGIC CLASS
- ANGIOGENESIS INHIBITORS
- MTOR INHIBITORS
- MONOCLONAL ANTIBODIES
- CYTOKINE IMMUNOTHERAPY (IL-2)
- DRUGS BY THERAPEUTIC CLASS
- DIAGNOSTICS
- IMAGING TEST
- BIOPSY
- BLOOD TEST
- OTHER DIAGNOSTICS
- DRUGS
- GEOGRAPHICAL ANALYSIS
- ASIA PACIFIC
- CHINA
- JAPAN
- INDIA
- SOUTH KOREA
- AUSTRALIA & NEW ZEALAND
- THAILAND
- INDONESIA
- VIETNAM
- REST OF ASIA PACIFIC
- ASIA PACIFIC
- COMPANY PROFILES
- ABBOTT LABORATORIES
- AMGEN INC
- BAYER AG
- BECTON, DICKINSON AND COMPANY (BD)
- BRISTOL-MYERS SQUIBB COMPANY
- EXELIXIS
- HOFFMANN-LA ROCHE
- MERCK & CO INC
- MERCK KGAA
- NOVARTIS INTERNATIONAL AG
- NXSTAGE MEDICAL INC
- PFIZER INC
- SEATTLE GENETIC
LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS
TABLE 2: RISK FACTORS DEVELOPING KIDNEY CANCER
TABLE 3: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 4: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 5: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 6: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 7: ASIA PACIFIC THERAPEUTIC CLASS DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 8: ASIA PACIFIC THERAPEUTIC CLASS DRUGS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 9: ASIA PACIFIC PHARMACOLOGIC CLASS DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 10: ASIA PACIFIC PHARMACOLOGIC CLASS DRUGS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 11: ASIA PACIFIC DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 12: ASIA PACIFIC DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 13: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 14: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
LIST OF FIGURES
FIGURE 1: PORTER’S FIVE FORCE ANALYSIS
FIGURE 2: OPPORTUNITY MATRIX
FIGURE 3: VENDOR LANDSCAPE
FIGURE 4: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, IN 2019
FIGURE 5: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CLEAR CELL RCC, 2019-2028 (IN $ MILLION)
FIGURE 6: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY PAPILLARY RCC, 2019-2028 (IN $ MILLION)
FIGURE 7: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CHROMOPHOBE RCC, 2019-2028 (IN $ MILLION)
FIGURE 8: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA, 2019-2028 (IN $ MILLION)
FIGURE 9: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY OTHER KIDNEY CANCERS, 2019-2028 (IN $ MILLION)
FIGURE 10: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, IN 2019
FIGURE 11: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUGS, 2019-2028 (IN $ MILLION)
FIGURE 12: ASIA PACIFIC THERAPEUTIC DRUG CLASS MARKET, BY TARGETED THERAPY, 2019-2028 (IN $ MILLION)
FIGURE 13: ASIA PACIFIC THERAPEUTIC DRUG CLASS MARKET, BY IMMUNOTHERAPY, 2019-2028 (IN $ MILLION)
FIGURE 14: ASIA PACIFIC THERAPEUTIC DRUG CLASS MARKET, BY OTHER THERAPEUTIC CLASS, 2019-2028 (IN $ MILLION)
FIGURE 15: ASIA PACIFIC PHARMACOLOGIC CLASS MARKET, BY ANGIOGENESIS INHIBITORS, 2019-2028 (IN $ MILLION)
FIGURE 16: ASIA PACIFIC PHARMACOLOGIC CLASS MARKET, BY MTOR INHIBITORS, 2019-2028 (IN $ MILLION)
FIGURE 17: ASIA PACIFIC PHARMACOLOGIC CLASS MARKET, BY MONOCLONAL ANTIBODIES, 2019-2028 (IN $ MILLION)
FIGURE 18: ASIA PACIFIC PHARMACOLOGIC CLASS MARKET, BY CYTOKINE IMMUNOTHERAPY (IL-2), 2019-2028 (IN $ MILLION)
FIGURE 19: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2019-2028 (IN $ MILLION)
FIGURE 20: ASIA PACIFIC DIAGNOSTICS MARKET, BY IMAGING TEST, 2019-2028 (IN $ MILLION)
FIGURE 21: ASIA PACIFIC DIAGNOSTICS MARKET, BY BIOPSY, 2019-2028 (IN $ MILLION)
FIGURE 22: ASIA PACIFIC DIAGNOSTICS MARKET, BY BLOOD TEST, 2019-2028 (IN $ MILLION)
FIGURE 23: ASIA PACIFIC DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2019-2028 (IN $ MILLION)
FIGURE 24: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
FIGURE 25: CHINA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 26: JAPAN KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 27: INDIA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 28: SOUTH KOREA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 29: AUSTRALIA & NEW ZEALAND KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 30: THAILAND KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 31: INDONESIA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 32: VIETNAM KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 33: REST OF ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
- GEOGRAPHICAL ANALYSIS
- ASIA PACIFIC
- CHINA
- JAPAN
- INDIA
- SOUTH KOREA
- AUSTRALIA & NEW ZEALAND
- THAILAND
- INDONESIA
- VIETNAM
- REST OF ASIA PACIFIC
- ASIA PACIFIC
- MARKET BY CANCER TYPE
- CLEAR CELL RCC
- PAPILLARY RCC
- CHROMOPHOBE RCC
- UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA
- OTHER KIDNEY CANCERS
- MARKET BY COMPONENT
- DRUGS
- DRUGS BY THERAPEUTIC CLASS
- TARGETED THERAPY
- IMMUNOTHERAPY
- OTHER THERAPEUTIC CLASS
- DRUGS BY PHARMACOLOGIC CLASS
- ANGIOGENESIS INHIBITORS
- MTOR INHIBITORS
- MONOCLONAL ANTIBODIES
- CYTOKINE IMMUNOTHERAPY (IL-2)
- DRUGS BY THERAPEUTIC CLASS
- DIAGNOSTICS
- IMAGING TEST
- BIOPSY
- BLOOD TEST
- OTHER DIAGNOSTICS
- DRUGS
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.